![Mark Rus](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark Rus
Director Ejecutivo en Delix Therapeutics, Inc. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Nicholas Haft | M | 35 |
Delix Therapeutics, Inc.
![]() Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | - |
David E. Olson | M | - |
Delix Therapeutics, Inc.
![]() Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | - |
Paul Conley | M | 56 |
Delix Therapeutics, Inc.
![]() Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | 6 años |
Vasudev Bailey | M | - |
Delix Therapeutics, Inc.
![]() Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | 3 años |
Nick Haft | M | - |
Delix Therapeutics, Inc.
![]() Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | 5 años |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 5 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Mark Rus
- Red Personal